

Antibiotic Resistance-A Growing Threat

Kiran Manda, *Pilli Gitanjali, *Manepalli Purna Kamakshi Sri Mahati

Department of Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram-
534202, West Godavari District.

Corresponding email: gitanjalipilli@gmail.com, mahathimanepalli2004@gmail.com

ABSTRACT: Antibiotic resistance is a serious problem that affects the whole world. It happens because people use too many antibiotics or not the right way. These resistant bacteria can make people sick more easily and spread quickly. New drugs are not coming fast enough, and it takes time and money to develop them. This could lead to infections that can't be treated and more deaths. To stop this, it's important to use antibiotics properly through programs that guide their use and by educating people. Using narrow-spectrum antibiotics helps target only the harmful bacteria, which lowers the chance of resistance. Phage therapy uses viruses to kill bad bacteria. Natural substances from plants, like polyphenols and alkaloids, also have antibacterial effects. Antimicrobial proteins from animals and humans are another hopeful option. Everyone, including doctors, leaders, and regular people, needs to work together. Acting early can help keep antibiotics useful and prevent a big health disaster.

KEYWORDS: Antibiotic Resistance, Antimicrobial Stewardship, Bacterial Infections, Plant-Derived Antimicrobials, Public Health.

INTRODUCTION

Antibiotics have been very important in changing how modern medicine works. They started as simple things back in the early 1900s but became some of the strongest tools doctors use to fight infections. These infections used to kill millions of people, but antibiotics helped save many lives. The story began with Salvarsan in 1910 and really took off when

Alexander Fleming discovered penicillin in 1928. This discovery started what is called the "golden era" of antibiotics, which reached its peak in the 1950s with many new antibiotics found from natural sources. These medicines work in different ways. Some stop bacteria from building their cell walls, others stop them from making proteins or copying their genetic material, and some mess up their basic chemical

processes. Out of all these ways, stopping the bacteria from making their cell walls is the most common and effective method used.(1)

Despite being life-saving, antibiotics have been made and used too much. Over the last 60 years, millions of tons have been created and given out—not just in human medicine but also in farming and raising animals. This has led to bacteria changing quickly and becoming resistant to antibiotics, which are often called "superbugs". These bacteria can live on even the strongest antibiotics. One big problem in fighting antibiotic resistance is how easy it is to get these drugs. In many places, antibiotics can be bought without a doctor's prescription. This makes people use them without proper guidance, take the wrong amount, or use them when they aren't needed. These actions all help make bacteria stronger and less responsive to treatment.(2)

Now, the drug companies are having a hard time keeping up with how fast bacteria are changing. Instead of making brand-new antibiotics, they are mostly trying to tweak the old ones to work better. But this isn't a long-term solution unless we also control how antibiotics are used and teach people about them properly. The growing problem of antibiotic resistance isn't just a scientific issue—it's a big crisis for society.(3)

We need immediate action around the world, like better rules on using antibiotics,

educating the public, investing in new research, and encouraging responsible use. Without these steps, we could face a time when common infections become deadly again.(4)

INCEPTION OF ANTIBIOTIC RESISTANCE

The World Health Organization (WHO) explains that antimicrobial resistance happens when microorganisms develop ways to survive even when exposed to antimicrobial drugs. Antibiotic resistance is a key part of this, meaning bacteria become able to live on even when antibiotics are used to kill or stop them.(5)

EARLY EMERGENCE OF RESISTANCE

The issues of bacteria becoming resistant to antibiotics started soon after these medicines were first used in medical treatment. When penicillin was discovered in the 1940s, it was a big breakthrough for treating infections caused by Staphylococcus bacteria. However, even back in 1942, doctors found that some strains of Staphylococcus were already resistant to penicillin. To deal with this, a new type of antibiotic called methicillin was developed and introduced in 1961. Methicillin was designed to work against bacteria that could break down penicillin. But soon after, in the 1980s, strains of Staphylococcus aureus that were resistant to methicillin started appearing, showing

that bacteria can quickly change and become resistant to new drugs.(6)

A similar situation happened with fluoroquinolones. These drugs were first used to treat infections caused by gram-negative bacteria, but later they were also used for gram-positive bacteria like *Staphylococcus*. This change in how they were used led to the quick development of resistance in *Staphylococcus aureus*, making fluoroquinolones less effective against these bacteria.(7)

As bacteria became more resistant to the first and second types of antibiotics, vancomycin became the final option for treating MRSA. But even this drug had its limits. In 1997, Japan found the first case of a strain that was partly resistant to vancomycin, called VISA. Later, fully vancomycin-resistant strains, known as VRSA, started appearing around the world.

REAL-WORLD EXAMPLES OF RESISTANCE

Several outbreaks have shown how serious antibiotic resistance can be in real life: In 2018, a retirement community in Vermont had an outbreak of *Shigella sonnei*. This bacteria was resistant to two common antibiotics, azithromycin and ciprofloxacin. Because of this, the usual treatments didn't work as well. This shows why it's important to use specific guidelines to choose the right antibiotics for resistant infections. A study in Thailand found that antibiotics

once used to treat diarrheal diseases, like tetracycline, ampicillin, and trimethoprim-sulfamethoxazole, were no longer working against certain types of infections. This shows how resistance can change in different areas, making it harder to find effective treatments.(8)

ANTIBIOTIC USE IN ANIMAL HUSBANDRY

A major, however regularly ignored, supporter to anti-microbial resistance is rural utilize, especially in creature cultivation. Anti-microbials are utilized not as it were to treat and avoid illnesses but moreover as development promoters, where they offer assistance creatures pick up weight quicker. This hone is particularly concerning since it applies dosages over long periods, perfect conditions for resistance to develop.(9)

One of the foremost disturbing illustrations includes glycopeptide anti-microbials, such as vancomycin (utilized in human pharmaceuticals) and avoparcin (utilized in creature bolster). Since they share comparable instruments of activity, resistance created against one can influence the other. In Denmark (1994), whereas as it were 24 kg of vancomycin was utilized for human treatment, 24,000 kg of avoparcin was included to creature feed thousand fold distinction. This abuse driven to the rise of vancomycin-resistant enterococci (VRE) in

animals, which afterward made their way into human populations.(10)

Antibiotic-resistant microscopic organisms starting in creatures can reach people via:

Contaminated meat and creature products, Direct contact with animals, Environmental pathways (e.g., water runoff from farms).

One key case is the development of safe non-typhoidal Salmonella serovars, which cause salmonellosis in people. These diseases become harder to treat when resistance creates, altogether constraining treatment alternatives for both veterinarians and doctors.(11)




Figure 1. Antibiotic Use in Denmark (1994). Comparison of vancomycin use in humans and avoparcin use in animals in Denmark during 1994. The disproportionate use of avoparcin in livestock feed (24,000 kg) compared to vancomycin in human therapy (24 kg) demonstrates the significant role of agricultural antibiotic use in the emergence of vancomycin-resistant enterococci (VRE).




Figure 2. Rising Antibiotic Resistance Over Time. Trends in the proportion of resistant isolates of *Staphylococcus aureus*, *Salmonella*, and *Shigella* from 1952 to 2016. The figure illustrates a steady increase in resistance rates across multiple bacterial species, reflecting the global rise of antimicrobial resistance over the decades.




Figure 3. Sources of Antibiotic Resistance. Pie chart depicting the major contributors to antibiotic resistance: agricultural use (40%), human overprescription (30%), poor infection control (15%), and environmental factors (15%).

PROGRESSION OF ANTIBIOTIC RESISTANCE

Anti-microbial resistance emerges through hereditary, plasmid-mediated, and non-genetic mechanisms, frequently driven by abuse and particular weight from anti-microbial exposure.

HEREDITARY BASIS

Resistance is created through chromosomal mutations, Mutations may affect, Target particles (where antibiotics act), Drug take-up systems, Regulatory systems.(12)

PLASMID-MEDIATED RESISTANCE

Resistance qualities are carried on plasmids, transferred between microscopic organisms by means of conjugation or transduction, leads to multidrug resistance over species.

NON-GENETIC BASIS

Drug detachment due to abscesses (e.g., TB), Stationary stage bacteria (no development = no mediate target), Lack of cell divider, as in protoplasts/spheroplasts, makes a few microbes normally resistant.(13)

CONTRIBUTING FACTORS

Selective pressure from anti-microbial overuse, Inappropriate use (e.g., for viral diseases, fragmented dosing), Sharing/saving medication, self-prescribing poor healthcare access, particularly in creating locales and low-income groups.

INSTRUMENTS OF RESISTANCE

lactamase proteins crush antibiotics, Mobile genetic elements (e.g., SCCmec) carry resistance genes, Target-site mutations (e.g., DNA gyrase for fluoroquinolone resistance)

Resistance to one anti-microbial can lead to cross-resistance inside its course (e.g., tetracycline, aminocycline, oxytetracycline)

AN IMPACT OF ANTIBIOTIC RESISTANCE

In 2016, a clinic in Modern Delhi, India, confronted a genuine flare-up of multidrug-resistant *Klebsiella pneumoniae* carrying the NDM-1 quality, which rendered the microscopic organisms safe to last-line anti-microbials like carbapenems and colistin.

This flare-up highlighted the grave results of antimicrobial resistance counting expanded quiet mortality, delayed clinic remains, and constrained treatment alternatives. Financially, it led to higher healthcare costs and strained healing center assets. On an open wellbeing level, the hazard of community spread and overpowered disease reconnaissance frameworks became apparent. Contributing variables included abuse and abuse of anti-microbials, over-the-counter accessibility, destitute disease control homes, and broad anti-microbial utilization in agribusiness. In reaction, the clinic executed disease control conventions, medicine reviews, and

antimicrobial stewardship programs. This case underscores the pressing need for facilitated endeavors to combat anti-microbial resistance universally.(14)

REGULATORY ISSUES RELATED TO ANTIBIOTIC RESISTANCE

In spite of developing worldwide mindfulness of anti-microbial resistance (AMR), the advancement of modern anti-microbials remains inadequate. Dr. Hana Balkhy of the WHO notes that the 43 anti-microbials as of now within the investigated pipeline fall flat enough to address existing resistance challenges. Hospital-acquired diseases, especially from multidrug-resistant pathogens, influence over 1.7 million individuals yearly within the U.S. alone, expanding both treatment costs and mortality. In numerous nations, anti-microbials can still be acquired without a medicine, and the need for authorization of standard treatment rules leads to far reaching abuse. This regulatory gap accelerates the spread of resistance. AMR could be a multi-dimensional wellbeing emergency that influences everybody, from researchers to the common open. Handling it requires facilitated endeavors, counting antimicrobial stewardship programs, national anti-microbial approaches, and strict observing of medicine hones. Mechanical devices can too offer assistance to move forward understanding adherence

to anti-microbial regimens. As customary medicines lose viability, elective procedures like resistant treatment, inactive immunization, and phage treatment are picking up intrigued. Phage treatment, especially in combination with anti-microbials, appears guaranteed in overcoming safe diseases, in spite of the fact that more investigation is required to address its impediments and guarantee secure, compelling utilization.(1)

EMERGING RESISTANT PATHOGENS

A few safe pathogens have risen as noteworthy worldwide dangers. A few of the foremost concerning include:

Multidrug-resistant tuberculosis (MDR-TB): Tuberculosis (TB) remains one of the deadliest irresistible maladies around the world. MDR-TB, which is safe from first-line anti-microbials, has made treatment more troublesome and costly.

Carbapenem-resistant Enterobacteriaceae (CRE): These microscopic organisms are safe to carbapenems, a lesson of anti-microbials regularly utilized as a final line of defense. CRE contaminations have tall mortality rates and restricted treatment options.

Neisseria gonorrhoeae: The microbes that cause gonorrhea have created resistance to numerous classes of anti-microbials, making it harder to treat this common sexually transmitted infection.

Clostridioides difficile (*C. difficile*): *C. difficile* diseases are frequently related with anti-microbial utilize, and the development of safe strains has driven to higher rates of repeat and expanded mortality.(16)

COMBATTING ANTIBIOTIC RESISTANCE

Tending to anti-microbial resistance requires a multifaceted approach that incorporates both anticipation and advancement. A few of the key techniques include:

Stewardship of Anti-microbial Utilize: Anti-microbial stewardship programs are fundamental to guarantee that anti-microbials are endorsed as it were when essential which the correct antibiotics are utilized at the proper doses for the proper length. Healthcare suppliers must take after evidence-based rules to play down the chance of resistance.

Regulation of Anti-microbial Utilize in Farming: Forbidding or confining the utilize of anti-microbials for development advancement in creatures is pivotal. Moreover, veterinary rules ought to guarantee that anti-microbials are as they were utilized when vital to treat sickness, not for prophylactic purposes.

Infection Anticipation and Control: Improved hygiene, sterilization, and disease control measures in healthcare offices can decrease the spread of safe

microbes. Upgraded reconnaissance to track safe strains is additionally essential.

Public Instruction: Open mindfulness campaigns can teach people on the dangers of abuse and abuse of anti-microbials. Empowering patients to total the complete course of anti-microbials and not self-medicate can offer assistance to decrease the development of resistance.(17)

Innovation and Development of Modern Anti-microbials: The pharmaceutical industry must prioritize the investigation and advancement of unused anti-microbials. Whereas the improvement of unused anti-microbials has moderated in later a long time, there's a pressing need to find novel drugs competent in treating safe infections.

Alternative Treatments: Researchers are investigating elective treatments such as phage treatment, which employ bacteriophages (infections that contaminate microbes) to target particular pathogens, as well as other medications like antimicrobial peptides and immunizations.(18)

CHALLENGES IN TACKLING RESISTANCE

Restricted access to fast diagnostics, Weak authorization of regulations, Lack of open awareness, Inadequate worldwide coordination.

FUTURE PERSPECTIVES AND RECOMMENDATIONS

Advance judicious anti-microbial utilization through instruction and stewardship programs. Enhance reconnaissance and information sharing at territorial and worldwide levels.(19) Support investigation and development in diagnostics, antibodies, and antimicrobials. Encourage universal collaboration via worldwide wellbeing organizations.(20)

CONCLUSION

Anti-microbial resistance speaks to an approaching emergency that rises above national borders and influences all perspectives of advanced medication and open wellbeing. The quick rise and spread of safe pathogens undermine decades of therapeutic advance, making once-treatable contaminations possibly dangerous. In spite of expanding mindfulness and progressing worldwide endeavors, challenges such as lacking direction, destitute observation framework, and need of advancement proceed to obstruct progress.

Addressing anti-microbial resistance requires a facilitated, multisectoral approach established within the One Wellbeing concept, including human, creature, and natural wellbeing. Future procedures must center on improving anti-microbial stewardship, moving forward to diagnostics, contributing in inquiry about and improvement, and cultivating worldwide cooperation.

Only through supported commitment and worldwide solidarity can we defend the viability of existing anti-microbials and guarantee a more advantageous future for eras to come.

REFERENCES

1. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Current Opinion in Microbiology*. 2019 Oct 1;51:72–80. Available from: <https://doi.org/10.1016/j.mib.2019.10.008>
2. Salam MdA, Al-Amin MdY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial resistance: a growing serious threat for global public health. *Healthcare*. 2023 Jul 5;11(13):1946. Available from: <https://doi.org/10.3390/healthcare11131946>
3. Haque H, Imam SI, Fatima H, Zaidi SDEZ, Rangwala BS, Rangwala HS. The growing threat of antibiotic resistance: Addressing the urgency. *Journal of Advances in Medical and Pharmaceutical Sciences*. 2023 Apr 4;25(2):23–8. Available from: <https://doi.org/10.9734/jamps/2023/v25i2600>
4. Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A Review on Antibiotic Resistance: Alarm Bells

- are Ringing. *Cureus*. 2017 Jun 28; Available from: <https://doi.org/10.7759/cureus.1403>
5. Gharpure R, Friedman CR, Fialkowski V, Collins JP, Stryko J, Marsh ZA, et al. Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant *Shigella sonnei* Infections in a Retirement Community—Vermont, 2018. *Clinical Infectious Diseases*. 2021 May 12;74(3):455–60. Available from: <https://doi.org/10.1093/cid/ciab450>
 6. Abene S, Fidsa A a. AM. More bugs, no drugs: The growing threat of antibiotic resistance. *Contagion Live - Infectious Disease News & Expert Insights*. 2024 Dec 8; Available from: <https://www.contagionlive.com/view/more-bugs-no-drugs-the-growing-threat-of-antibiotic-resistance>
 7. Goossens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet*. 2005 Feb 1;365(9459):579–87. Available from: [https://doi.org/10.1016/s0140-6736\(05\)17907-0](https://doi.org/10.1016/s0140-6736(05)17907-0)
 8. Vaou N, Stavropoulou E, Voidarou C, Tsigalou C, Bezirtzoglou E. Towards Advances in Medicinal Plant Antimicrobial Activity: A review Study on Challenges and Future Perspectives. *Microorganisms*. 2021 Sep 27;9(10):2041. Available from: <https://doi.org/10.3390/microorganisms9102041>
 9. Davey P, Pagliari C, Hayes A. The patient's role in the spread and control of bacterial resistance to antibiotics. *Clinical Microbiology and Infection*. 2002 Jan 1;8:43–68. Available from: <https://doi.org/10.1046/j.1469-0691.8.s.2.6.x>
 10. Chopra I, Roberts M. Tetracycline Antibiotics: Mode of action, applications, molecular biology, and Epidemiology of Bacterial resistance. *Microbiology and Molecular Biology Reviews*. 2001 Jun 1;65(2):232–60. Available from: <https://doi.org/10.1128/mmbr.65.2.232-260.2001>
 11. Kattupalli S, Chatla S. Antibiotic resistance- reasons and control measures. *International Journal of Pharmacy and Biological Sciences*. 2019 Jan 1;1–1:503–8. Available from: https://www.ijpbs.com/ijpbsadmin/upload/ijpbs_5c7366fe66dc3.pdf
 12. World Health Organization: WHO. Antimicrobial resistance. 2023.

- Available from:
<https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
13. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now. *Drug Resistance Updates*. 2011 Mar 25;14(2):118–24. Available from: <https://doi.org/10.1016/j.drug.2011.02.003>
 - 2021-global-shortage-of-innovative-antibiotics-fuels-emergence-and-spread-of-drug-resistance
 16. Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: Norovirus, *Clostridium difficile*, and *Acinetobacter* species. *American Journal of Infection Control*. 2010 Jun 1;38(5):S25–33. Available from: <https://doi.org/10.1016/j.ajic.2010.04.196>
 17. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. *Clinical Microbiology Reviews*. 2000 Oct
 14. Pierce GN, Resch C, Mourin M, Dibrov P, Dibrov E, Ravandi A. Bacteria and the growing threat of multidrug resistance for invasive cardiac interventions. *Reviews in Cardiovascular Medicine*. 2022 Jan 14;23(1). Available from: <https://doi.org/10.31083/j.rcm2301015>
 - World Health Organization: WHO. Global shortage of innovative antibiotics fuels emergence and spread of drug-resistance. 2021 Apr 15; Available from: [https://www.who.int/news/item/15-04-1;13\(4\):602–14](https://www.who.int/news/item/15-04-1;13(4):602–14). Available from: <https://doi.org/10.1128/cmr.13.4.602>
 18. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World Journal of Gastrointestinal Pharmacology and Therapeutics*. 2017 Jan 1;8(3):162. Available from: <https://doi.org/10.4292/wjgpt.v8.i3.162>
 19. Forsythe. The rising threat of antibiotic resistance - IEEE pulse. *IEEE Pulse*. 2023. Available from: <https://www.embs.org/pulse/articles/the-rising-threat-of-antibiotic-resistance/>

20. The danger of antibiotic overuse.

Nemours KidsHealth. Available from:

<https://kidshealth.org/en/parents/antibiotic-overuse.html>



BTS International
Advanced
Pharmaceutical
Sciences Journal